In this issue of Cancer Cell, Bluemn et al. report that ∼20% of metastatic castration-resistant prostate cancers express neither AR nor neuroendocrine genes and show AR pathway-independent growth, driven instead by a FGFR/MAPK/ID1 signaling cascade. These results provide a strong rationale for co-targeting AR bypass pathways with initial AR antagonism.

中文翻译：

---

雄激素受体途径非依赖性前列腺癌的细胞起源及其治疗意义。

在本期《癌细胞》中，Bluemn等人。报告指出，约有20％的转移性去势抵抗性前列腺癌既不表达AR也不表达神经内分泌基因，并且不依赖于FGFR / MAPK / ID1信号级联反应而显示AR途径非依赖性生长。这些结果为将AR旁路与最初的AR拮抗作用共同定位提供了有力的依据。